Gluteus Medius Latent Trigger Point and Muscle Strength in Healthy Subjects

• ClinicalTrials.gov Identifier: NCT04640558
• Recruitment Status: Completed
• First Posted: November 23, 2020
• Last Update Posted: January 29, 2021
• Sponsor: Kars State Hospital
• Information provided by (Responsible Party): Fatih Bagcier, Kars State Hospital

Study Description

Brief Summary:

This study aimed to investigate the relationship between latent MTrPs and gluteus medius muscle strength in a group of healthy adults.

Condition or disease	Intervention/treatment
Myofascial Pain Syndrome; Muscle Weakness	Device: Muscle strength measurement

Detailed Description:

Latent myofascial trigger points (MTrPs) do not cause spontaneous pain; however, they may lead to a limited range of motion and muscle weakness. We hypothesized that latent MTrPs might decrease gluteus medius muscle strength in healthy individuals. Forty-eight healthy men will be included in the study. Trigger point examination for the gluteus medius will be performed bilaterally. Subjects with one or more trigger points on the dominant side and those without any trigger points will be assigned to two groups. Muscle strength for gluteus medius will be assessed with a manual muscle tester using the "break test" technique on both sides. The subjects and the examiners will be blinded. For statistical analysis, the independent sample t-test was used to compare the intergroup differences.

Study Design

• Study Type: Observational [Patient Registry]
• Actual Enrollment: 48 participants
• Observational Model: Other
• Time Perspective: Prospective
• Target Follow-Up Duration: 4 Weeks
• Official Title: The Relationship Between Gluteus Medius Latent Trigger Point and Muscle Strength in Healthy Subjects
• Actual Study Start Date: November 17, 2020
• Actual Primary Completion Date: January 17, 2021
• Actual Study Completion Date: January 17, 2021

Groups and Cohorts

Group/Cohort	Intervention/treatment
Group 1. Latent Myofascial Trigger Point Group; 24 participants who will be clinically diagnosed with unilateral latent myofascial trigger point in the dominant side gluteus medius muscle.	Device: Muscle strength measurement; The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
Group 2. Non-Latent Myofascial Trigger Point Group; 24 participants who don't have latent myofascial trigger point.	Device: Muscle strength measurement; The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded

Outcome Measures

Primary Outcome Measures :

1. Gluteus medius muscle strength [ Time Frame: One month ]
   In the participant's side-lying position, the practitioner will be applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants will be asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements will be repeated three times, one minute apart, on the right and left sides. The mean of the measurements will be calculated and recorded

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 40 Years (Adult)
• Sexes Eligible for Study: Male
• Sampling Method: Probability Sample

Study Population

24 participants who are clinically diagnosed with unilateral latent MTrP in the dominant side gluteus medius muscle and 24 participants who don't have latent MTrP.

Criteria

Inclusion Criteria:

• Patient age: 18-40 years.
• Absence of musculoskeletal complaints related to the lumbar, sacroiliac, and hip area.
• Absence of bilateral latent MTrP in the gluteus medius muscle.
• Latent trigger point in the gluteus medius muscle on the dominant side with palpation.

Exclusion Criteria:

• A history of medical treatment, physical therapy, injection therapy, or surgical treatment related to the lumbar, sacroiliac, and hip area.
• History of trauma, or malignancy or being pregnant, or if the patient is in the lactation period.
• Bilateral latent MTrP in the gluteus medius muscle.
• Presence of latent MTrP on the non-dominant side.

Contacts and Locations

Locations

Turkey

Biruni University Faculty of Medicine

İstanbul, Turkey, 34100

Sponsors and Collaborators

Kars State Hospital

More Information

• Responsible Party: Fatih Bagcier, Medical Doctor, Kars State Hospital
• ClinicalTrials.gov Identifier: NCT04640558
• Other Study ID Numbers: KarsSH
• First Posted: November 23, 2020
• Last Update Posted: January 29, 2021
• Last Verified: January 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Fatih Bagcier, Kars State Hospital:

Trigger point; Gluteus medius muscle

Additional relevant MeSH terms:

Muscle Weakness; Myofascial Pain Syndromes; Fibromyalgia; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Pathologic Processes; Rheumatic Diseases; Neuromuscular Diseases